Gitnux/Report 2026

Psychiatric Industry Statistics

The U.S. mental health treatment market was valued at $118 billion in 2025, explore the psychiatric figures behind growth, companies and trends.
33Statistics
39Sources
8Sections
1Visuals
17mRead
Psychiatric Industry Statistics
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 28 days

01 Industry overview

The psychiatric industry at a glance

The U.S. mental health treatment market was valued at $118 billion in 2025, supported by rising treatment use, telehealth adoption, workforce shortages and continued pharmaceutical innovation.

$118B[21]
U.S. market size, 2025
6.9%[21]
U.S. market CAGR, 2025–2030
27,980[15]
U.S. psychiatrists employed, 2025
22.9%[22]
U.S. adults receiving treatment, 2024
Market size
The U.S. mental health treatment market was estimated at $118 billion in 2025. The estimate covers outpatient and inpatient mental health and substance-use treatment centers, psychiatric hospitals, mental-health applications and related services.[21]
Forecast & CAGR
The U.S. market is forecast to reach $159 billion by 2030, implying a 6.9% compound annual growth rate from 2025 through 2030.[21]
Market share & regions
North America, Asia-Pacific and Europe together accounted for 90% of global mental-wellness spending in 2025. The United States was the largest national market at $138.74 billion, followed by China at $18.29 billion and Canada at $13.81 billion.[23]
Segmentation
Outpatient care is the most widely offered specialty mental-health service, available at 77.0% of facilities in the cited industry overview. Other reported segments included crisis services at 47.0%, psychosocial rehabilitation at 41.0%, residential treatment at 17.0%, inpatient treatment at 16.0% and partial hospitalization at 15.0%.[24]
Pricing
U.S. psychiatrists had mean annual wages of $269,940 and mean hourly wages of $129.78 in May 2025. These are occupational wage measures rather than patient prices and include employed psychiatrists across industries.[15]
Trends, drivers & challenges
Demand is being driven by high prevalence and expanding treatment access: 61.5 million U.S. adults had any mental illness in 2024, while 52.1% of adults with any mental illness received treatment. Supply remains a constraint; BLS reported 27,980 employed psychiatrists in May 2025, and global evidence continues to show substantial gaps in workforce and service coverage.[22][15][25]
Consumer behavior & competition
In 2024, 22.9% of U.S. adults, or 60.1 million people, received mental-health treatment during the previous year; 16.7% used prescription medication and 12.8% received treatment through telehealth. Among adults with any mental illness, 52.1% received treatment, indicating both substantial demand and a large untreated population.[22]
M&A
Bristol Myers Squibb completed its acquisition of Karuna Therapeutics for total consideration of $14.0 billion, or $12.9 billion net of cash acquired. The transaction added Cobenfy, an antipsychotic approved by the FDA in September 2024 for adult schizophrenia.[26]
Regulation
U.S. mental-health insurance regulation is being shaped by the 2024 Mental Health Parity and Addiction Equity Act final rule. General requirements apply to plan years beginning on or after January 1, 2025, while several comparative-analysis and outcomes-related provisions apply from January 1, 2026.[27]
Latest news
In April 2026, the FDA announced actions to accelerate research and development of treatments for serious mental illness, including psychedelic therapies, and issued priority vouchers and research-related measures. In the same month, the agency approved Auvelity for agitation associated with Alzheimer’s disease dementia, the first FDA-approved non-antipsychotic treatment for that condition.[28]

02 Ranking

Top 10 Companies in the Psychiatric Industry

The leading companies in the psychiatric industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 20, 2026 · Next review December 20, 2026

Verdict

Eli Lilly and Company stands out for schizophrenia and bipolar disorder drug coverage because its Zyprexa (olanzapine) is a landmark psychiatric drug, while Johnson & Johnson focuses on schizophrenia and bipolar disorder long-acting therapies since Sprycado (paliperidone palmitate) and Invega are marketed globally.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in psychiatric drugs

    Eli Lilly and Company

    US

    Ranked #1 · 9.6 · Psychiatric drugs

    Why we picked it: Its psychiatric drug portfolio includes Zyprexa (olanzapine), and it reported an operating margin of 40.4%.

  2. #2 overall

    Johnson & Johnson

    US

    Ranked #2 · 9.1 · Psychiatric drugs

    Why we picked it: Its schizophrenia and bipolar franchises include Sprycado and Invega, backed by R&D at 15.6% of revenue.

  3. #3 overall

    Astrazeneca

    GB

    Ranked #3 · 9.0 · Psychiatric drugs

    Why we picked it: Its psychiatry franchise includes Seroquel (quetiapine), supported by an operating margin of 23.4%.

Pick 1 is the #1 company overall. No other segment places in the top 5, so picks 2 and 3 follow rank.

Full ranking

Sort by
Top 10 companies in the psychiatric industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Eli Lilly and Company

Psychiatric drugs · US

9.6
2

Johnson & Johnson

Psychiatric drugs · US

9.1
3

Astrazeneca

Psychiatric drugs · GB

9.0
4

H. Lundbeck

Psychiatric drugs · DK

8.8
5

Neurocrine Biosciences

Psychiatric drugs · US

8.7
6

Universal Health Services

Behavioral health hospitals and outpatient services, US and UK · US

8.7
7

Otsuka Pharmaceutical

Psychiatric pharmaceuticals, including antipsychotics and CNS treatments · JP

8.6
8

LifeStance Health

Outpatient psychiatry and mental healthcare, United States · US

8.5
9

Teva Pharmaceutical Industries

Generic psychiatric pharmaceuticals, global · IL

8.5
10

Viatris

Psychiatric generic and branded pharmaceuticals, global · US

7.8

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 20, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 20). Top 10 companies in the psychiatric industry. In Psychiatric Industry Statistics. Gitnux. https://gitnux.org/psychiatric-industry-statistics/#top-companies

report visual · Comparison

State mental health agency expenditure per capita (United States)

Oregon leads with 640.8 USD per capita.

Oregon640.8 USD per capita
Vermont463.2 USD per capita
New York430.1 USD per capita
Pennsylvania410.6 USD per capita
Iowa401.7 USD per capita
District of Columbia384.6 USD per capita
source-verifiedcms.nri-inc.org

04 Statistics

Technology & AI

AI use among psychiatrists remains partial. In January 10–February 1, 2026, 53% of active APA-member psychiatrists reported not using AI in practice.

AI and automation in the psychiatric industry

  • 44% of surveyed psychiatrists had used ChatGPT-3.5 and 33% had used GPT-4 to assist with clinical questions; the online survey was conducted in 2023–2024.[1]
  • 53% of active practicing APA-member psychiatrists in the U.S. and Canada had not used AI in practice; the survey was fielded January 10–February 1, 2026.[2]
  • 26% of active practicing APA-member psychiatrists in the U.S. and Canada used AI for clinical note-taking, while 16% used it for administrative tasks; fielded January 10–February 1, 2026.[2]

05 Statistics

Market Intelligence

Provider-side markets show large telehealth participation and sizable clinic revenue pools. U.S. psychiatry clinic market size was $18.5 billion in 2025.

Market size and service revenue in the psychiatric industry

  • $10.53 billion was 2024 revenue for U.S. psychiatric and substance-abuse hospitals, the broader NAICS 6222 category that includes psychiatric hospital services.[3]
  • $18.5 billion was the U.S. psychiatry clinic market size in 2025, covering outpatient psychiatric services, inpatient psychiatric services, telepsychiatry and other psychiatry-clinic services.[4]

Demand shifts in the psychiatric industry

  • Telehealth accounted for 53.4% of mental-health-provider visits for metropolitan patients with private insurance versus 21.7% for nonmetropolitan patients during 2021–2023.[5]
  • Psychiatry, behavioral health and mental health were offered through telehealth by 189 of 197 behavioral-health programs surveyed in 2024, indicating psychiatry was the dominant behavioral-health telehealth service.[6]
  • Substance-use-disorder services were offered by 96 of the same 197 behavioral-health telehealth programs in 2024, versus 189 programs offering psychiatry, behavioral health or mental health services.[6]

06 Statistics

Strategy & Growth

Deal activity concentrates in add-ons and expansion, with continued mental-health transaction volume. Beacon Behavioral Partners completed 4 outpatient-psychiatry add-on acquisitions in Q1 2026.

M&A and consolidation in the psychiatric industry

  • 65 behavioral-health private-equity deals were tracked in the United States in 2024: 35 add-ons, 16 leveraged buyouts and 14 growth or expansion investments.[7]
  • 4 outpatient-psychiatry add-on acquisitions were completed by Beacon Behavioral Partners in the United States during Q1 2026.[8]
  • 68 North American behavioral-health transactions occurred in H1 2024, with mental-health transactions representing 35% of the sector's transactions in the source's classification.[9]
  • 51% of North American behavioral-health transactions were sponsor-led and 49% were strategic during the twelve months ending June 30, 2024.[9]
  • 11 acquisitions were completed by Beacon Behavioral Partners in the United States in 2024, including 9 acquisitions involving psychiatric practices.[7]
  • 19 mental-health transactions closed in the United States in Q1 2026, the largest behavioral-health sub-sector by traditional M&A volume; the source defines mental health broadly to include psychiatric and related services.[8]

07 Statistics

Operating Benchmarks

Telepsychiatry operation is widespread across practice types. In 2023, 94% of APA members conducted at least some telepsychiatry.

Operating metrics used in the psychiatric industry

  • 94% of 1,660 American Psychiatric Association members conducted at least some telepsychiatry in 2023; the survey covered APA-member psychiatrists and related psychiatric practitioners.[10]
  • 94.9% of U.S. private-practice psychiatry physicians worked in practices using telehealth in 2024, based on 116 respondents to the AMA Physician Practice Benchmark Survey.[11]
  • 92.4% of U.S. hospital-owned psychiatry physicians worked in practices using telehealth in 2024, based on 60 respondents to the AMA Physician Practice Benchmark Survey.[11]
  • 82% of 1,660 APA survey respondents delivered telehealth through all or mostly video in 2023; the measure covers telepsychiatry delivery modality.[10]

08 Statistics

Delivery & Operations

Capacity measures indicate inpatient and residential bed availability as a constraint signal. In 2023, 36,150 state psychiatric hospital beds for adults with severe mental illness were available.

Delivery capacity and installed base in the psychiatric industry

  • 88,434 inpatient and residential mental-health treatment beds were available in the United States in 2023, including 58,244 inpatient beds and 30,190 residential beds.[12]
  • 36,150 state psychiatric hospital beds for adults with severe mental illness were available in the United States in 2023, equal to 10.8 beds per 100,000 people.[13]
  • 52,592 active psychiatrists, equal to 19 psychiatrists per 100,000 people, were available in the United States in 2024; this is a practitioner-capacity measure, and no newer national count was identified.[14]

09 Statistics

People & Workforce

Workforce constraints show up alongside elevated pay measures. In May 2025, U.S. psychiatrists had a mean annual wage of $269,940.

Pay and labour costs in the psychiatric industry

  • $281,870 was the median annual wage for U.S. psychiatrists in May 2025.[15]
  • $269,940 was the mean annual wage for U.S. psychiatrists in May 2025; the mean hourly wage was $129.78.[15]
  • $240,000 was the median salary for undifferentiated psychiatrists at surveyed U.S. behavioral-health agencies in 2024; the all-agency mean was $262,234.[16]

Work models and delivery locations in the psychiatric industry

  • 94% of surveyed U.S. psychiatrists conducted at least some telepsychiatry in 2023, and most reported operating in a hybrid environment with a physical practice location.[10]
  • 16% of surveyed U.S. psychiatrists reported having no physical practice and seeing patients only remotely in 2023.[10]
  • 83.1% of U.S. psychiatrists provided a video visit during the week before the 2022 AMA survey; 54.1% delivered more than 20% of visits by videoconference.[17]

10 Statistics

Pricing

Self-pay pricing varies widely by metro, while payer rates for key codes are set nationally. In November 2026, the median posted self-pay fee for a psychiatric follow-up visit was $200.

Fees and price levels in the psychiatric industry

  • $400 was the median posted self-pay fee for an adult first psychiatric evaluation across 51 U.S. psychiatry practices, with metro medians ranging from $250 in Houston to $1,550 in the San Francisco Bay Area, in November 2026.[18]
  • Medicare’s 2026 national non-facility payment rates were $202.08 for CPT 90792 psychiatric diagnostic evaluation with medical services, $173.35 for CPT 90791 without medical services, and $135.61 for CPT 99214 moderate-complexity established-patient visits.[19]
  • $200 was the median posted self-pay fee for a psychiatric follow-up visit across 51 U.S. psychiatry practices in November 2026; metro medians ranged from $150 in Nashville to $475 in Minneapolis–St. Paul.[18]

11 Statistics

Risk & Compliance

Physical restraint reporting varies by state among inpatient psychiatric facilities. Alaska reported 0.12 hours of physical-restraint use per 1,000 hours of patient care in 2024.

Incidents, safety and loss events in the psychiatric industry

  • 0.12 hours of physical-restraint use per 1,000 hours of patient care were reported by Alaska inpatient psychiatric facilities in the 2024 CMS quality dataset.[20]
  • 0.81 hours of physical-restraint use per 1,000 hours of patient care were reported by Connecticut inpatient psychiatric facilities in the 2024 CMS quality dataset.[20]
  • 0.06 hours of physical-restraint use per 1,000 hours of patient care were reported by Alabama inpatient psychiatric facilities in the 2024 CMS quality dataset.[20]

Key questions about the psychiatric industry

What is the size of the U.S. mental health treatment market, and what definition is used?
The U.S. mental health treatment market was valued at $118 billion in 2025. The estimate covers outpatient and inpatient mental health and substance-use treatment centers, psychiatric hospitals, mental-health applications and related services.
How fast is the U.S. market expected to grow through 2030?
The U.S. market is forecast to reach $159 billion by 2030. This implies a 6.9% compound annual growth rate from 2025 through 2030.
Which companies lead the psychiatric industry?
Eli Lilly and Company stands out for schizophrenia and bipolar disorder drug coverage because its Zyprexa (olanzapine) is a landmark psychiatric drug, while Johnson & Johnson focuses on schizophrenia and bipolar disorder long-acting therapies since Sprycado (paliperidone palmitate) and Invega are marketed globally.
What is changing in clinical technology adoption among psychiatrists?
In surveys fielded January 10–February 1, 2026, 53% of active APA-member psychiatrists had not used AI in practice. Among users, 26% used AI for clinical note-taking and 16% used it for administrative tasks.
What does the market structure look like across service settings?
Outpatient care was the most widely offered specialty mental-health service, available at 77.0% of facilities in the cited overview. Other reported segments included crisis services at 47.0% and residential treatment at 17.0%.
How do telehealth and medication use show up in treatment behavior?
In 2024, 22.9% of U.S. adults received mental-health treatment during the previous year, with 16.7% using prescription medication and 12.8% receiving treatment through telehealth. Telehealth accounted for 53.4% of mental-health-provider visits for metropolitan patients with private insurance versus 21.7% for nonmetropolitan patients during 2021–2023.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 20). Psychiatric Industry Statistics. Gitnux. https://gitnux.org/psychiatric-industry-statistics
MLA
Samuel Norberg. "Psychiatric Industry Statistics." Gitnux, 20 Nov 2026, https://gitnux.org/psychiatric-industry-statistics.
Chicago
Samuel Norberg. 2026. "Psychiatric Industry Statistics." Gitnux. https://gitnux.org/psychiatric-industry-statistics.